Eliem Therapeutics (ELYM) Competitors $2.25 -0.07 (-3.02%) As of 09/23/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ELYM vs. CCCC, TKNO, TNXP, OGI, VYGR, AVIR, JBIO, PBYI, HRTX, and AARDShould you be buying Eliem Therapeutics stock or one of its competitors? The main competitors of Eliem Therapeutics include C4 Therapeutics (CCCC), Alpha Teknova (TKNO), Tonix Pharmaceuticals (TNXP), Organigram Global (OGI), Voyager Therapeutics (VYGR), Atea Pharmaceuticals (AVIR), Jade Biosciences (JBIO), Puma Biotechnology (PBYI), Heron Therapeutics (HRTX), and Aardvark Therapeutics (AARD). These companies are all part of the "pharmaceutical products" industry. Eliem Therapeutics vs. Its Competitors C4 Therapeutics Alpha Teknova Tonix Pharmaceuticals Organigram Global Voyager Therapeutics Atea Pharmaceuticals Jade Biosciences Puma Biotechnology Heron Therapeutics Aardvark Therapeutics C4 Therapeutics (NASDAQ:CCCC) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends. Does the media favor CCCC or ELYM? In the previous week, C4 Therapeutics had 10 more articles in the media than Eliem Therapeutics. MarketBeat recorded 10 mentions for C4 Therapeutics and 0 mentions for Eliem Therapeutics. C4 Therapeutics' average media sentiment score of 0.39 beat Eliem Therapeutics' score of 0.00 indicating that C4 Therapeutics is being referred to more favorably in the media. Company Overall Sentiment C4 Therapeutics Neutral Eliem Therapeutics Neutral Which has more volatility & risk, CCCC or ELYM? C4 Therapeutics has a beta of 2.98, meaning that its stock price is 198% more volatile than the S&P 500. Comparatively, Eliem Therapeutics has a beta of -0.39, meaning that its stock price is 139% less volatile than the S&P 500. Do analysts prefer CCCC or ELYM? C4 Therapeutics presently has a consensus price target of $8.50, indicating a potential upside of 288.13%. Given C4 Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe C4 Therapeutics is more favorable than Eliem Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score C4 Therapeutics 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is CCCC or ELYM more profitable? Eliem Therapeutics has a net margin of 0.00% compared to C4 Therapeutics' net margin of -325.88%. Eliem Therapeutics' return on equity of -47.03% beat C4 Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets C4 Therapeutics-325.88% -53.91% -33.26% Eliem Therapeutics N/A -47.03%-45.97% Which has stronger valuation and earnings, CCCC or ELYM? Eliem Therapeutics has lower revenue, but higher earnings than C4 Therapeutics. Eliem Therapeutics is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioC4 Therapeutics$35.58M4.38-$105.32M-$1.58-1.39Eliem TherapeuticsN/AN/A-$35.12M-$0.53-4.25 Do insiders and institutionals believe in CCCC or ELYM? 78.8% of C4 Therapeutics shares are owned by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are owned by institutional investors. 8.7% of C4 Therapeutics shares are owned by company insiders. Comparatively, 4.7% of Eliem Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryC4 Therapeutics beats Eliem Therapeutics on 11 of the 15 factors compared between the two stocks. Get Eliem Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELYM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ELYM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELYM vs. The Competition Export to ExcelMetricEliem TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$66.94M$756.90M$5.75B$10.39BDividend YieldN/A4.84%5.77%4.64%P/E Ratio-4.251.1975.7726.11Price / SalesN/A26.17544.74124.93Price / CashN/A17.6537.5461.24Price / Book0.586.4712.876.30Net Income-$35.12M-$5.42M$3.29B$271.03M7 Day Performance6.13%-0.64%-0.26%-0.15%1 Month Performance-5.46%5.14%3.84%6.41%1 Year Performance-59.09%29.53%68.35%28.81% Eliem Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELYMEliem TherapeuticsN/A$2.25-3.0%N/A-65.7%$66.94MN/A-4.259CCCCC4 Therapeutics3.4592 of 5 stars$3.41-4.5%$8.67+154.2%-61.5%$242.69M$34.24M-2.16150Analyst ForecastGap UpTKNOAlpha Teknova2.7597 of 5 stars$4.52-0.2%$10.00+121.2%+20.4%$241.87M$37.74M-10.76240Positive NewsTNXPTonix Pharmaceuticals3.3258 of 5 stars$27.12-2.3%$70.00+158.1%+90.0%$237.84M$10.09M-0.6950Analyst RevisionOGIOrganigram Global1.2951 of 5 stars$1.76+2.9%N/A+0.6%$235.93M$223.82M35.21860Positive NewsVYGRVoyager Therapeutics4.1451 of 5 stars$4.25+1.0%$13.25+211.7%-29.6%$235.74M$42.58M-2.30100News CoveragePositive NewsAVIRAtea Pharmaceuticals2.1195 of 5 stars$2.97-2.3%$6.00+102.0%-17.1%$235.69MN/A-1.8470News CoveragePositive NewsJBIOJade Biosciences2.4072 of 5 stars$7.14+1.0%$16.00+124.1%N/A$232.98MN/A-0.2420Positive NewsPBYIPuma Biotechnology4.0064 of 5 stars$4.52-2.6%$7.00+54.9%+85.1%$227.67M$230.50M4.61200Positive NewsHRTXHeron Therapeutics4.07 of 5 stars$1.24flat$4.50+262.9%-36.2%$227.32M$144.29M-62.00300Positive NewsAARDAardvark Therapeutics3.2335 of 5 stars$10.26+3.1%$32.60+217.7%N/A$222.64MN/A0.0018Analyst ForecastHigh Trading Volume Related Companies and Tools Related Companies C4 Therapeutics Alternatives Alpha Teknova Alternatives Tonix Pharmaceuticals Alternatives Organigram Global Alternatives Voyager Therapeutics Alternatives Atea Pharmaceuticals Alternatives Jade Biosciences Alternatives Puma Biotechnology Alternatives Heron Therapeutics Alternatives Aardvark Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELYM) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eliem Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eliem Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
